Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Bendamustine
Related studies linked through entity extraction aliases.
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
- Status
- TERMINATED
- Phase
- PHASE3
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
- Status
- COMPLETED
- Phase
- PHASE2
BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
CyBeR Association in Relapsed/Refractory DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
- Status
- TERMINATED
- Phase
- PHASE3
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
- Status
- WITHDRAWN
- Phase
- PHASE3
Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting
- Status
- TERMINATED
- Phase
- PHASE2